What Is Chronic Myeloid Leukemia?

This content has been reviewed and approved by

Hagop M. Kantarjian, MD
Chairman & Professor, Leukemia Department
MD Anderson Cancer Center
University of Texas
 

Chronic myeloid leukemia (CML) is a cancer of the blood in which too many granulocytes, a type of white blood cell, are produced in bone marrow. Normally, bone marrow cells mature into several different types of blood cells. CML affects the young blood cells (called blasts).

An estimated 4,830 new cases of CML will be diagnosed in 2008, according to the American Cancer Society. CML is most common in older adults. The average age of diagnosis is about 55 to 60 years, with children only making up 2 percent of cases, according to the American Cancer Society.

The main function of granulocytes is to destroy bacteria. The blasts do not completely mature and become too numerous. They live longer than normal granulocytes and accumulate in the bone marrow and blood.

Initially in CML, there is a gradual increase in mature, abnormal myeloid cells in the bone marrow. These cells eventually spill into the blood and other organs, causing symptoms, such as fatigue from anemia or an enlarged spleen.

The increase in leukemia cell numbers occurs slowly at first and is referred to as the chronic phase. Eventually, the leukemia cells begin to increase more rapidly, resulting in the accelerated and blastic phases. CML can occur over a period of months or years.

Like most cancers, early detection and treatment can help control the disease or eliminate it from your body.

This content was last modified on August 11, 2007 .
Latest Cancer News
ZevalinĀ® Confirmed Effective for Patients with Follicular Lymphoma Who Have Failed an Autologous Transplant

September 5, 2008 — Researchers from France have reported that five of eight patients with follicular lymphoma who had failed an autologous stem cell transplant achieved a complete remission with standard doses of Zevalin® (Yttrium-90 ((90)Y) ibritumomab tiuxetan). The details of this study appeared in an early online publication in Leukemia-Lymphoma of July 15, 2008.

Forty Percent of Postmenopausal Breast Cancers Preventable by Lifestyle Changes

September 5, 2008 — Researchers from the University of Wisconsin-Madison, the H. Lee Moffitt Cancer Center, Dartmouth Medical School, and the Fred Hutchinson Cancer Center have reported that 40.7% of postmenopausal breast cancer can be prevented by changes in lifestyle. The details of this study appeared in the August 15, 2008 issue of the American Journal of Epidemiology.

US FDA lists drugs under safety probes

September 5, 2008 — WASHINGTON (Reuters) - U.S. health officials said on Friday they are probing safety concerns with Eli Lilly and Co's antidepressant Cymbalta, Biogen Idec and Elan Corp's multiple sclerosis drug Tysabri and more than a dozen other medicines.

Select news items provided by Reuters Health